Data Presented at TCT Reinforce Edwards Lifesciences’ Commitment to Structural Heart Innovation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Citi Removes Two names from 90-Day Catalyst Watch Lists
October 31, 2024 4:06 PM EDTCiti Removes Two names from 90-Day Catalyst Watch Lists
Tandem Diabetes (NASDAQ: TNDM) Removed from 90-Day Downside Catalyst Watch List: "With our 3Q24 Preview (10/1/24), we opened a 90-day Negative Catalyst Watch on TNDM. The thesis was: 1) survey results suggested ~flat Tandem share of new patient starts in the U.S. in the 3Q24E; 2) while Mobi prescriptions were increasing, it... MoreGoldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)
October 30, 2024 4:16 PM EDTGoldman Sachs analyst David Roman reiterated a Buy rating and $80.00 price target on Edwards Lifesciences (NYSE: EW).
The analyst comments "Overall, we think confirmatory results for the full cohort of TRISCEND II was broadly expected by investors we have spoken... More
